Administration of Adipose-derived Stem Cells Extracellular Vesicles in a Murine Model of Spinal Muscular Atrophy: Effects of a New Potential Therapeutic Strategy

Overview

Journal Stem Cell Res Ther

Publisher Biomed Central

Date 2024 Apr 2

PMID 38561840

Authors

Federica Virla

Ermanna Turano

Ilaria Scambi

Lorenzo Schiaffino

Marina Boido

Raffaella Mariotti

Affiliations

Soon will be listed here.

Abstract

Background: Spinal Muscular Atrophy (SMA) is an autosomal-recessive neuromuscular disease affecting children. It is caused by the mutation or deletion of the survival motor neuron 1 (SMN1) gene resulting in lower motor neuron (MN) degeneration followed by motor impairment, progressive skeletal muscle paralysis and respiratory failure. In addition to the already existing therapies, a possible combinatorial strategy could be represented by the use of adipose-derived mesenchymal stem cells (ASCs) that can be obtained easily and in large amounts from adipose tissue. Their efficacy seems to be correlated to their paracrine activity and the production of soluble factors released through extracellular vesicles (EVs). EVs are important mediators of intercellular communication with a diameter between 30 and 100 nm. Their use in other neurodegenerative disorders showed a neuroprotective effect thanks to the release of their content, especially proteins, miRNAs and mRNAs.

Methods: In this study, we evaluated the effect of EVs isolated from ASCs (ASC-EVs) in the SMNΔ7 mice, a severe SMA model. With this purpose, we performed two administrations of ASC-EVs (0.5 µg) in SMA pups via intracerebroventricular injections at post-natal day 3 (P3) and P6. We then assessed the treatment efficacy by behavioural test from P2 to P10 and histological analyses at P10.

Results: The results showed positive effects of ASC-EVs on the disease progression, with improved motor performance and a significant delay in spinal MN degeneration of treated animals. ASC-EVs could also reduce the apoptotic activation (cleaved Caspase-3) and modulate the neuroinflammation with an observed decreased glial activation in lumbar spinal cord, while at peripheral level ASC-EVs could only partially limit the muscular atrophy and fiber denervation.

Conclusions: Our results could encourage the use of ASC-EVs as a therapeutic combinatorial treatment for SMA, bypassing the controversial use of stem cells.

Citing Articles

Therapeutic potential of adipose-derived stem cell extracellular vesicles: from inflammation regulation to tissue repair.

Zhou B, Chen Q, Zhang Q, Tian W, Chen T, Liu Z Stem Cell Res Ther. 2024; 15(1):249.

PMID: 39113098 PMC: 11304935. DOI: 10.1186/s13287-024-03863-5.

References

Verhaart I, Robertson A, Wilson I, Aartsma-Rus A, Cameron S, Jones C . Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017; 12(1):124. PMC: 5496354. DOI: 10.1186/s13023-017-0671-8. View

Kolb S, Kissel J . Spinal muscular atrophy: a timely review. Arch Neurol. 2011; 68(8):979-84. PMC: 3860273. DOI: 10.1001/archneurol.2011.74. View

Mercuri E, Pera M, Scoto M, Finkel R, Muntoni F . Spinal muscular atrophy - insights and challenges in the treatment era. Nat Rev Neurol. 2020; 16(12):706-715. DOI: 10.1038/s41582-020-00413-4. View

Wirth B, Karakaya M, Kye M, Mendoza-Ferreira N . Twenty-Five Years of Spinal Muscular Atrophy Research: From Phenotype to Genotype to Therapy, and What Comes Next. Annu Rev Genomics Hum Genet. 2020; 21:231-261. DOI: 10.1146/annurev-genom-102319-103602. View

Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L . Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995; 80(1):155-65. DOI: 10.1016/0092-8674(95)90460-3. View

Lorson C, Hahnen E, Androphy E, Wirth B . A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A. 1999; 96(11):6307-11. PMC: 26877. DOI: 10.1073/pnas.96.11.6307. View

Wirth B, Brichta L, Schrank B, Lochmuller H, Blick S, Baasner A . Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. 2006; 119(4):422-8. DOI: 10.1007/s00439-006-0156-7. View

Chaytow H, Faller K, Huang Y, Gillingwater T . Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine. Cell Rep Med. 2021; 2(7):100346. PMC: 8324491. DOI: 10.1016/j.xcrm.2021.100346. View

Imlach W, Beck E, Choi B, Lotti F, Pellizzoni L, McCabe B . SMN is required for sensory-motor circuit function in Drosophila. Cell. 2012; 151(2):427-39. PMC: 3475188. DOI: 10.1016/j.cell.2012.09.011. View

10.

Hamilton G, Gillingwater T . Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med. 2012; 19(1):40-50. DOI: 10.1016/j.molmed.2012.11.002. View

11.

Park G, Maeno-Hikichi Y, Awano T, Landmesser L, Monani U . Reduced survival of motor neuron (SMN) protein in motor neuronal progenitors functions cell autonomously to cause spinal muscular atrophy in model mice expressing the human centromeric (SMN2) gene. J Neurosci. 2010; 30(36):12005-19. PMC: 2944776. DOI: 10.1523/JNEUROSCI.2208-10.2010. View

12.

Simone C, Ramirez A, Bucchia M, Rinchetti P, Rideout H, Papadimitriou D . Is spinal muscular atrophy a disease of the motor neurons only: pathogenesis and therapeutic implications?. Cell Mol Life Sci. 2015; 73(5):1003-20. PMC: 4756905. DOI: 10.1007/s00018-015-2106-9. View

13.

Abati E, Citterio G, Bresolin N, Comi G, Corti S . Glial cells involvement in spinal muscular atrophy: Could SMA be a neuroinflammatory disease?. Neurobiol Dis. 2020; 140:104870. DOI: 10.1016/j.nbd.2020.104870. View

14.

Custer S, Androphy E . Autophagy dysregulation in cell culture and animals models of spinal muscular atrophy. Mol Cell Neurosci. 2014; 61:133-40. PMC: 4135029. DOI: 10.1016/j.mcn.2014.06.006. View

15.

Piras A, Schiaffino L, Boido M, Valsecchi V, Guglielmotto M, De Amicis E . Inhibition of autophagy delays motoneuron degeneration and extends lifespan in a mouse model of spinal muscular atrophy. Cell Death Dis. 2017; 8(12):3223. PMC: 5870600. DOI: 10.1038/s41419-017-0086-4. View

16.

Sansa A, Miralles M, Beltran M, Celma-Nos F, Caldero J, Garcera A . ERK MAPK signaling pathway inhibition as a potential target to prevent autophagy alterations in Spinal Muscular Atrophy motoneurons. Cell Death Discov. 2023; 9(1):113. PMC: 10076363. DOI: 10.1038/s41420-023-01409-x. View

17.

Hensel N, Baskal S, Walter L, Brinkmann H, Gernert M, Claus P . ERK and ROCK functionally interact in a signaling network that is compensationally upregulated in Spinal Muscular Atrophy. Neurobiol Dis. 2017; 108:352-361. DOI: 10.1016/j.nbd.2017.09.005. View

18.

Alrafiah A, Karyka E, Coldicott I, Iremonger K, Lewis K, Ning K . Plastin 3 Promotes Motor Neuron Axonal Growth and Extends Survival in a Mouse Model of Spinal Muscular Atrophy. Mol Ther Methods Clin Dev. 2018; 9:81-89. PMC: 5852384. DOI: 10.1016/j.omtm.2018.01.007. View

19.

Baglio S, Pegtel D, Baldini N . Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. Front Physiol. 2012; 3:359. PMC: 3434369. DOI: 10.3389/fphys.2012.00359. View

20.

Uccelli A, Moretta L, Pistoia V . Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2009; 8(9):726-36. DOI: 10.1038/nri2395. View